Arrowhead Pharmaceuticals ( (ARWR) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arrowhead Pharmaceuticals shares are jumping as traders react to fresh takeover chatter, after RBC Capital Markets named the biotech as a prime acquisition target. The move is amplified by strong momentum in RNA interference therapeutics, where peers such as Alnylam are also advancing.
Bullish sentiment is further supported by Arrowhead’s drug candidate zodasiran progressing into Phase 3 trials, signaling late-stage potential. Investors are also taking note of growing institutional interest, with large funds reportedly building positions and reinforcing confidence in the stock’s outlook.
More about Arrowhead Pharmaceuticals
YTD Price Performance: -15.24%
Average Trading Volume: 2,907,495
Technical Sentiment Signal: Buy
Current Market Cap: $7.94B
For further insights into ARWR stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.